Eligo Bioscience Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
46
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
15
Eligo Bioscience General Information
Description
Developer of antibiotics intended to treat microbiome precision and bacteria-associated diseases. The company's antibiotics combine sequencing systems with engineered phage capsids, to develop antimicrobials that are used to eradicate resistant pathogens or virulent bacteria within the human microbiome, enabling pharmaceutical companies to make medicines from pathogen-resistant antimicrobials.
Contact Information
Website
www.eligo.bioCorporate Office
- 111 Avenue De France
- 75013 Paris
- France
Corporate Office
- 111 Avenue De France
- 75013 Paris
- France
Eligo Bioscience Timeline
Eligo Bioscience Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 12. Later Stage VC | 03-May-2024 | Completed | Generating Revenue | |||
| 11. Later Stage VC (Series B) | 05-Dec-2023 | Completed | Generating Revenue | |||
| 10. Grant | 30-Jun-2020 | Completed | Generating Revenue | |||
| 9. Grant | 01-May-2019 | Completed | Generating Revenue | |||
| 8. Grant | 01-Jan-2019 | Completed | Generating Revenue | |||
| 7. Early Stage VC (Series A) | 26-Sep-2017 | Completed | Generating Revenue | |||
| 6. Accelerator/Incubator | 01-Jan-2017 | Completed | Generating Revenue | |||
| 5. Grant | 20-Sep-2016 | $2.47M | $2.16M | Completed | Generating Revenue | |
| 4. Early Stage VC (Series A) | 01-Apr-2015 | $2.16M | $2.16M | Completed | Generating Revenue |
Eligo Bioscience Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| B | ||||||||
| A | 266,666 | $0.047727 | $8.95 | $8.95 | 1x | $8.95 | 11.97% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Eligo Bioscience Comparisons
Industry
Financing
Details
Eligo Bioscience Competitors (55)
One of Eligo Bioscience’s 55 competitors is GangaGen, a Venture Capital-Backed company based in Bangalore, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| GangaGen | Venture Capital-Backed | Bangalore, India | ||||
| Locus Biosciences | Venture Capital-Backed | Morrisville, NC | ||||
| Vedanta Biosciences | Venture Capital-Backed | Cambridge, MA | ||||
| NovaBiotics | Venture Capital-Backed | Aberdeen, United Kingdom | ||||
| BiomX | Formerly VC-backed | Gaithersburg, MD |
Eligo Bioscience Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Eligo Bioscience Patents
Eligo Bioscience Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250032528-A1 | Method for treating c. acnes bacteria-associated diseases | Pending | 24-Jul-2023 | ||
| US-20230114520-A1 | Engineered bifidobacterium strains comprising a transgene | Pending | 07-Oct-2021 | ||
| US-20230126159-A1 | Engineered bacterial strains comprising a transgene | Pending | 07-Oct-2021 | ||
| US-20220364063-A1 | Production of lytic phages | Active | 12-May-2021 | ||
| US-20220364062-A1 | Production bacterial cells and use thereof in production methods | Active | 12-May-2021 | C12N7/00 |
Eligo Bioscience Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Eligo Bioscience Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Vives Fund | Venture Capital | Minority | ||
| Sanofi Ventures | Corporate Venture Capital | Minority | ||
| CARB-X | University | |||
| European Commission | Government | |||
| EASME - EU Executive Agency for SMEs | Corporation | Minority |
Eligo Bioscience FAQs
-
When was Eligo Bioscience founded?
Eligo Bioscience was founded in 2014.
-
Where is Eligo Bioscience headquartered?
Eligo Bioscience is headquartered in Paris, France.
-
What is the size of Eligo Bioscience?
Eligo Bioscience has 46 total employees.
-
What industry is Eligo Bioscience in?
Eligo Bioscience’s primary industry is Biotechnology.
-
Is Eligo Bioscience a private or public company?
Eligo Bioscience is a Private company.
-
What is Eligo Bioscience’s current revenue?
The current revenue for Eligo Bioscience is .
-
How much funding has Eligo Bioscience raised over time?
Eligo Bioscience has raised $51.6M.
-
Who are Eligo Bioscience’s investors?
Vives Fund, Sanofi Ventures, CARB-X, European Commission, and EASME - EU Executive Agency for SMEs are 5 of 15 investors who have invested in Eligo Bioscience.
-
Who are Eligo Bioscience’s competitors?
GangaGen, Locus Biosciences, Vedanta Biosciences, NovaBiotics, and BiomX are some of the 55 competitors of Eligo Bioscience.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
